June 3, 2022Expert Review of Medical Devices
Antithrombotic therapy after transcatheter aortic valve implantation
Key result
Current evidence supports a monotherapy paradigm prioritizing oral anticoagulants or single antiplatelet therapy after transcatheter aortic valve implantation.
Why the study?
TAVI carries a risk of thrombotic complications requiring prevention, but bleeding is a major drawback, necessitating antithrombotic therapy tailored to individual risk.
What is the optimal antithrombotic therapy strategy after transcatheter aortic valve implantation to minimize thrombotic and bleeding complications?
Structured PICO
What is the optimal antithrombotic therapy strategy after transcatheter aortic valve implantation to minimize thrombotic and bleeding complications?
P
Population
Patients with symptomatic severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI)
I
Intervention
Tailored antithrombotic therapy (oral anticoagulant or single antiplatelet therapy)
O
Outcome
Thrombotic and bleeding complications
The review highlights that current guidelines favor a monotherapy approach (OAC or SAPT) after TAVI to optimize the balance between bleeding and thrombotic risks.
Authors
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Supports monotherapy after TAVI to reduce bleeding; reinforces Level 1 evidence for de-escalation.
Cite This Study
Greco et al. (2022) conducted a review in Symptomatic severe aortic stenosis undergoing TAVI. Antithrombotic therapy was evaluated. Current evidence supports a monotherapy paradigm prioritizing oral anticoagulants or single antiplatelet therapy after transcatheter aortic valve implantation.